These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 21856022

  • 21. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study.
    Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, Khan BV.
    Circulation; 2005 Jan 25; 111(3):343-8. PubMed ID: 15655130
    [Abstract] [Full Text] [Related]

  • 22. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension.
    Chiou KR, Chen CH, Ding PY, Chen YT, Ting CT, Huang JL, Chiang AH, Liu CP, Tseng CJ, Chao CT, Chang MS.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May 25; 63(5):368-76. PubMed ID: 10862446
    [Abstract] [Full Text] [Related]

  • 23. [The effect of angiotensin-II receptor antagonists on the vasoconstriction mechanisms in chronic heart failure].
    Korzh AN, Balkovaia LB, Bondarenko TI.
    Lik Sprava; 2000 May 25; (3-4):34-7. PubMed ID: 10921256
    [Abstract] [Full Text] [Related]

  • 24. Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure.
    Kum LC, Yip GW, Lee PW, Lam YY, Wu EB, Chan AK, Fung JW, Chan JY, Zhang Q, Kong SL, Yu CM.
    Int J Cardiol; 2008 Mar 28; 125(1):16-21. PubMed ID: 17433840
    [Abstract] [Full Text] [Related]

  • 25. Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes.
    Cetinkalp SS, Karadeniz MM, Erdogan MA, Ozgen GA, Yilmaz CO.
    Saudi Med J; 2008 Oct 28; 29(10):1414-8. PubMed ID: 18946564
    [Abstract] [Full Text] [Related]

  • 26. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
    Strutz F, Bramlage P, Paar WD.
    Curr Med Res Opin; 2005 Sep 28; 21(9):1433-40. PubMed ID: 16197662
    [Abstract] [Full Text] [Related]

  • 27. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure.
    Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von Haehling S, Okonko DO, Leyva F, Proudler AJ, Coats AJ, Anker SD.
    J Am Coll Cardiol; 2005 Sep 20; 46(6):1019-26. PubMed ID: 16168285
    [Abstract] [Full Text] [Related]

  • 28. Irbesartan in patients with atrial fibrillation.
    ACTIVE I InvestigatorsPopulation Health Research Institute, McMaster University, Hamilton, ON, Canada., Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ.
    N Engl J Med; 2011 Mar 10; 364(10):928-38. PubMed ID: 21388310
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
    Mitrovic V, Willenbrock R, Miric M, Seferovic P, Spinar J, Dabrowski M, Kiowski W, Marks DS, Alegria E, Dukát A, Lenz K, Arens HA.
    Am Heart J; 2003 Mar 10; 145(3):E14. PubMed ID: 12660683
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Acute angiotensin II receptor blockade improves insulin-induced microvascular function in hypertensive individuals.
    Jonk AM, Houben AJ, Schaper NC, de Leeuw PW, Serné EH, Smulders YM, Stehouwer CD.
    Microvasc Res; 2011 Jul 10; 82(1):77-83. PubMed ID: 21514308
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effects of estradiol and the angiotensin II receptor blocker irbesartan on vascular function in postmenopausal women.
    Mirza FS, Ong P, Collins P, Okamura K, Gerhard-Herman M, Williams GH, Seely EW.
    Menopause; 2008 Jul 10; 15(1):44-50. PubMed ID: 18182939
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
    Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ.
    J Am Soc Nephrol; 2005 Oct 10; 16(10):3027-37. PubMed ID: 16120823
    [Abstract] [Full Text] [Related]

  • 40. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.
    Rector TS, Carson PE, Anand IS, McMurray JJ, Zile MR, McKelvie RS, Komajda M, Kuskowski M, Massie BM, I-PRESERVE Trial Investigators.
    Circ Heart Fail; 2012 Mar 01; 5(2):217-25. PubMed ID: 22267751
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.